A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature

Journal of Ultrasound in Medicine

Volumn 30, Issue 7, 2011, Pages 921-931

  Warram, Jason M ^a   Sorace, Anna G ^b   Saini, Reshu ^b   Umphrey, Heidi R ^a   Zinn, Kurt R ^a   Hoyt, Kenneth ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b and Radiation Oncology   (United States)

Author keywords

Contrast enhanced sonography; P selectin Triple targeted microbubbles; Tumor vasculature; Vascular endothelial growth factor receptor 2

Indexed keywords

BINS; BLOOD VESSELS; CELL ENGINEERING; ENDOTHELIAL CELLS; MAMMALS; MEDICAL IMAGING; ULTRASONIC IMAGING; ULTRASONOGRAPHY;

BREAST CANCER TUMORS; CONTRAST-ENHANCED SONOGRAPHIES; LINEAR ARRAY TRANSDUCERS; TARGETED MICROBUBBLES; TUMOR VASCULATURE; ULTRASOUND CONTRAST AGENT; ULTRASOUND SCANNERS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR;

TUMORS;

CONTRAST MEDIUM; PADGEM PROTEIN; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR;

ANALYSIS OF VARIANCE; ANGIOSARCOMA; ANIMAL; ARTICLE; ECHOGRAPHY; ENZYME IMMUNOASSAY; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; METABOLISM; MICROBUBBLE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANIMALS; CELL LINE, TUMOR; CONTRAST MEDIA; FLOW CYTOMETRY; HEMANGIOSARCOMA; IMMUNOENZYME TECHNIQUES; INTEGRIN ALPHAVBETA3; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MICROBUBBLES; NEOVASCULARIZATION, PATHOLOGIC; P-SELECTIN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79959596040     PISSN: 02784297     EISSN: None     Source Type: Journal    
DOI: 10.7863/jum.2011.30.7.921     Document Type: Article

References (33)

1. Hoyt K, Warram JM, Umphrey H, et al. Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks. J Ultrasound Med 2010; 29:577-585.
2. Guibal A, Taillade L, Mulé S, et al. Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy. Radiology 2010; 254:420-429.
3. Lamuraglia M, Bridal SL, Santin M, et al. Clinical relevance of contrastenhanced ultrasound in monitoring anti-angiogenic therapy of cancer: current status and perspectives. Crit Rev Oncol Hematol 2010; 73:202-212.
4. Willmann JK, Paulmurugan R, Chen K, et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008; 246:508-518.
5. Gramiak R, Shah PM. Echocardiography of the aortic root. Invest Radiol 1968; 3:356-366.
6. Ferrara K, Pollard R, Borden M. Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. Annu Rev Biomed Eng 2007; 9:415-447. (Pubitemid 350246663)
7. Lindner JR, Song J, Christiansen J, Klibanov AL, Xu F, Ley K. Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin. Circulation 2001; 104:2107-2112. (Pubitemid 33027054)
8. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer, II: correlations with proliferation and angiogenesis. J Pathol 1998; 184:53-57. (Pubitemid 28086153)
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell2000; 100:57-70.
10. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-257.
11. Kuehn R, Lelkes PI, Bloechle C, Niendorf A, Izbicki JR. Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer. Pancreas 1998; 18:96-103. (Pubitemid 29011342)
12. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007; 19:2003-2012. (Pubitemid 47354167)
13. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676. (Pubitemid 36749215)
14. Yan J, Jia R, Song H, et al. A promising new approach of VEGFR2-based DNA vaccine for tumor immunotherapy. Immunol Lett 2009; 126:60-66.
15. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001; 98:3352-3357. (Pubitemid 32220849)
16. Lee DJ, Lyshchik A, Huamani J, Hallahan DE, Fleischer AC. Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model. J Ultrasound Med 2008; 27:855-866. (Pubitemid 351913824)
17. Willmann JK, Lutz AM, Paulmurugan R, et al. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology 2008; 248:936-944.
18. Geng JG, Chen M, Chou KC. P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis. Curr Med Chem 2004; 11:2153-2160. (Pubitemid 38967736)
19. Stone JP, Wagner DD. P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer. J Clin Invest 1993; 92:804-813. (Pubitemid 23262402)
20. Caine GJ, Lip GY, Stonelake PS, Ryan P, Blann AD. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 2004; 92:185-190. (Pubitemid 39010882)
21. Ferrante EA, Pickard JE, Rychak J, Klibanov A, Ley K. Dual targeting improves microbubble contrast agent adhesion to VCAM-1 and P-selectin under flow. J Control Release 2009; 140:100-107.
22. Su CH, Chang CY, Wang HH, et al. Ultrasonic microbubble-mediated gene delivery causes phenotypic changes of human aortic endothelial cells. Ultrasound Med Biol 2010; 36:449-458.
23. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270:1500-1502. (Pubitemid 3005294)
24. Pignatelli M, Cardillo MR, Hanby A, Stamp GW. Integrins and their accessory adhesion molecules in mammary carcinomas: loss of polarization in poorly differentiated tumors. Hum Pathol 1992; 23:1159-1166.
25. Sheldrake HM, Patterson LH. Function and antagonism of beta3 integrins in the development of cancer therapy. Curr Cancer Drug Targets 2009; 9:519-540.
26. Lu X, Lu D, Scully M, Kakkar V. The role of integrins in cancer and the development of anti-integrin therapeutic agents for cancer therapy. Perspect Medicin Chem 2008; 2:57-73. (Pubitemid 351566493)
27. Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000; 6:3056-3061. (Pubitemid 30637728)
28. Willmann JK, Kimura RH, Deshpande N, Lutz AM, Cochran JR, Gambhir SS. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med 2010; 51:433-440.
29. Ellegala DB, Leong-Poi H, Carpenter JE, et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation 2003; 108:336-341. (Pubitemid 36899026)
30. Weller GE, Villanueva FS, Tom EM, Wagner WR. Targeted ultrasound contrast agents: in vitro assessment of endothelial dysfunction and multitargeting to ICAM-1 and sialyl Lewisx. Biotechnol Bioeng 2005; 92:780-788. (Pubitemid 41772473)
31. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics Int 2004; 7:36-42.
32. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264:569-571.
33. Parast CV, Mroczkowski B, Pinko C, Misialek S, Khambatta G, Appelt K. Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis. Biochemistry1998; 37:16788-16801. (Pubitemid 28543942)